RefleXion Medical, Inc discovered first-of-its-kind biology-guided radiotherapy* (BgRT) for the treatment of lung tumors.
It is the first and only technology which uses injected radiotracers to obtain active signals, called emissions, from each tumor to guide treatment delivery.
Biology-guided radiotherapy* (BgRT) BgRT has the potential to manage tumor motion with unprecedented precision with the continuous biological interaction between the radiotracer and the cancer cells. In addition, BgRT aims to expand treatment options for patients with all stages of cancer.
In U.S, lunge cancer is the most common cause of cancer, accounting for 25 percent of all cancer deaths. Lung tumors often spread quickly and patients may have multiple tumors at the time of diagnosis thus limitimg the use of standard radiation techniques in the lungs. Moreover, lungs are the most common location for metastatic tumors arising from cancers located in other parts of the body.
US Food and Drug Administration (FDA) grants Breakthrough Device Designation' for biology-guided radiotherapy* (BgRT) for the treatment of lung cancer.
